Postprandial insulin increase

1. Acarbose decreases postprandial insulin increase in humans (Relative postprandial insulin increase 1.09 versus 1.90 with placebo).

   “Relative postprandial insulin increase was 1.90 with placebo, 1.09 with acarbose, and 1.03 with metformin.”

   Human trialType 2 diabetes; standard meal test; compared with placebo3 x 100 mg/day24 weeksn = 94

   Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study

   The American journal of medicine·1 Dec 1997

2. Acarbose decreases postprandial insulin increase in humans (-80.7 pM).

   “but they showed a marked difference in 1-h postprandial insulin values (-80.7 pM with acarbose, 96.7 pM with glibenclamide).”

   Human trialdietary failure100 mg three times a day24 weeks

   Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study

   Diabetes care·1 Jun 1994

More on Acarbose

1. Metformin decreases postprandial insulin increase in humans (Relative postprandial insulin increase 1.03 versus 1.90 with placebo).

   “Relative postprandial insulin increase was 1.90 with placebo, 1.09 with acarbose, and 1.03 with metformin.”

   Human trialType 2 diabetes; standard meal test; compared with placebo2 x 850 mg/day24 weeksn = 94

   Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study

   The American journal of medicine·1 Dec 1997

More on Metformin

1. Glibenclamide increases postprandial insulin increase in humans (96.7 pM).

   “but they showed a marked difference in 1-h postprandial insulin values (-80.7 pM with acarbose, 96.7 pM with glibenclamide).”

   Human trialdietary failuremean dose 4.3 mg/day24 weeks

   Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study

   Diabetes care·1 Jun 1994

More on Glibenclamide